BLOG INSIGHTS

Erythropoietin Drugs    A glycoprotein hormone called erythropoietin (EPO) or hematopoietin stimulates the erythropoiesis process, which results in the creation of red blood cells in the bone marrow. The medicine erythropoietin was created with the intention of treating anaemic conditions brought on by dialysis and treatments for end stage renal disease (ESRD). Erythropoietin Drugs have been approved for chemotherapy-induced anaemia, which follows ESRD anaemia. Original biopharmaceutical companies focused on ART-induced anaemia after post-abbreviated new drug application (ANDA) approvals and the high success rate of EPO applications for chemotherapy-induced anaemia (among HIV patients). Drugs that mimic erythropoietin, a naturally occurring hormone secreted from the kidney, aid in the production of red blood cells (RBC) by enhancing the activity of bone marrow tissues. Raising the RBC count raises the blood's haemoglobin concentration, which helps the body's tissues carry eno...

  Hemoglobinopathy  Hemoglobinopathies are a group of congenital blood disorders that are caused by differences in haemoglobin structure and/or production. Hemoglobinopathies are single-gene illnesses that cause an aberrant structure in one of the globin chains of the haemoglobin molecule, preventing it from carrying oxygen across the body and resulting in anaemia or other medical problems. Hemoglobinopathy is a set of hereditary blood illnesses characterised by an anomaly in haemoglobin structure. Sickle cell disease (SCD) and thalassemia are two of these diseases. Severe discomfort, shortness of breath, an enlarged spleen, and growth issues in children are all common symptoms of the illness.Hemoglobinopathies are a set of illnesses characterised by faulty haemoglobin molecule synthesis or structure that are handed down via families (inherited). Sickle cell disease (SCD) is a blood illness characterised by defective haemoglobin, which causes red blood cells to be damaged and...